INFLUENCE OF HYPERCORTISOLEMIA ON SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR-II AND INTERLEUKIN-1 RECEPTOR ANTAGONIST RESPONSES TO ENDOTOXIN IN HUMAN-BEINGS

被引:46
|
作者
BARBER, AE
COYLE, SM
FISCHER, E
SMITH, C
VANDERPOLL, T
SHIRES, T
LOWRY, SF
机构
[1] SYNERGEN INC,BOULDER,CO 80301
[2] CORNELL UNIV,MED CTR,SURG METAB LAB,NEW YORK,NY 10021
关键词
D O I
10.1016/S0039-6060(05)80352-6
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. We have previously reported that the antecedent administration of glucocorticoids altered both the hormonal and proinflammatory cytokine responses to lipopolysaccharide (LPS) when administered to human volunteers. In that study, subjects with vastly exaggerated levels of tumor necrosis factor (TNF) and interleukin (IL)-6 12 and 144 hours after cortisol infusion exhibited hemodynamic and hormonal responses no different from those of untreated subjects after endotoxin. The current study examined levels of the antiinflammatory cytokines interleukin-1 receptor antagonist (IL-1ra) and soluble receptors to tumor necrosis factor (sTNF-R) in the same setting of the previous report. Methods. Hydrocortisone succinate was infused into healthy volunteers. LPS was then injected immediately or was delayed by 6, 12, or 144 hours (C, C-6, C-12, and C-144, respectively). Subjects receiving LPS alone served as controls. Plasma was analyzed to determine levels of TNF, sTNF-R and IL-1ra by enzyme-linked immunosorbent assay before administration of LPS and at 30-minute intervals after administration of LPS for 6 hours. Results. Levels of sTNF-R increased after PS administration in all groups (p < 0.05 versus baseline) with a significantly higher level recorded in the subjects having received hydrocortisone 144 hours before (C-144, p < 0.05 versus all other groups). TNF levels remained undetectable in association with immediate infusion of LPS (C) and the relatively short delay group (C6). This cytokine peaked 90 minutes after LPS in all other groups, with a significantly higher peak in the C-144 subjects when compared with controls. IL-1ra levels rose in all groups but to a lesser extent in the C group (p < 0.05). Conclusions. These data confirm that glucorticoids influence the production of both sTNF-R and IL-1ra. The potential for an exaggerated response of sTNF-R exists for an extended period of time after exposure to glucocorticoids.
引用
收藏
页码:406 / 411
页数:6
相关论文
共 50 条
  • [1] THE EFFECT OF SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR-II ON ENDOTOXIN-MEDIATED HEMODYNAMIC INSTABILITY
    ANDERSON, JA
    KNOTT, AW
    WILSON, MA
    GARRISON, RN
    SIMS, DE
    EDWARDS, MJ
    JOURNAL OF SURGICAL RESEARCH, 1995, 58 (01) : 53 - 57
  • [2] EFFECT OF INTERLEUKIN-1 RECEPTOR ANTAGONIST AND SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR IN ANIMAL-MODELS OF INFECTION
    PARIS, MM
    FRIEDLAND, IR
    EHRETT, S
    HICKEY, SM
    OLSEN, KD
    HANSEN, E
    THONAR, EJMA
    MCCRACKEN, GH
    JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (01): : 161 - 169
  • [3] INTRATRACHEAL ADMINISTRATION OF ENDOTOXIN AND CYTOKINES .7. THE SOLUBLE INTERLEUKIN-1 RECEPTOR AND THE SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR-II (P80) INHIBIT ACUTE-INFLAMMATION
    ULICH, TR
    YI, ES
    YIN, SM
    SMITH, C
    REMICK, D
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1994, 72 (01): : 137 - 140
  • [4] TUMOR-NECROSIS-FACTOR IS INVOLVED IN THE APPEARANCE OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN ENDOTOXEMIA
    VANDERPOLL, T
    VANDEVENTER, SJH
    TENCATE, H
    LEVI, M
    TENCATE, JW
    JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (03): : 665 - 667
  • [5] PERSISTENTLY ELEVATED SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR AND INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS IN CRITICALLY ILL PATIENTS
    ROGY, MA
    COYLE, SM
    OLDENBURG, HSA
    ROCK, CS
    BARIE, PS
    VANZEE, KJ
    SMITH, CG
    MOLDAWER, LL
    LOWRY, SF
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1994, 178 (02) : 132 - 138
  • [6] INDUCTION OF CIRCULATING SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR AND INTERLEUKIN-1 RECEPTOR ANTAGONIST FOLLOWING INTERLEUKIN-1-ALPHA INFUSION IN HUMANS
    TILG, H
    TREHU, E
    SHAPIRO, L
    PAPE, D
    ATKINS, MB
    DINARELLO, CA
    MIER, JW
    CYTOKINE, 1994, 6 (02) : 215 - 219
  • [7] Analysis of tumor necrosis factor-α, interleukin-6, interleukin-1β, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders
    Kaneyama, K
    Segami, N
    Sun, W
    Sato, J
    Fujimura, K
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 2005, 99 (03): : 276 - 284
  • [8] TUMOR NECROSIS FACTOR AND ENDOTOXIN INDUCE SIMILAR METABOLIC RESPONSES IN HUMAN-BEINGS
    MICHIE, HR
    SPRIGGS, DR
    MANOGUE, KR
    SHERMAN, ML
    REVHAUG, A
    ODWYER, ST
    ARTHUR, K
    DINARELLO, CA
    CERAMI, A
    WOLFF, SM
    KUFE, DW
    WILMORE, DW
    SURGERY, 1988, 104 (02) : 280 - 286
  • [9] CYTOKINES IN ACUTE MYOCARDIAL-INFARCTION - SELECTIVE INCREASE IN CIRCULATING TUMOR-NECROSIS-FACTOR, ITS SOLUBLE RECEPTOR, AND INTERLEUKIN-1 RECEPTOR ANTAGONIST
    LATINI, R
    BIANCHI, M
    CORREALE, E
    DINARELLO, CA
    FANTUZZI, G
    FRESCO, C
    MAGGIONI, AP
    MENGOZZI, M
    ROMANO, S
    SHAPIRO, L
    SIRONI, M
    TOGNONI, G
    TURATO, R
    GHEZZI, P
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1994, 23 (01) : 1 - 6
  • [10] Cytokine inhibitors:: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behcet's disease
    Düzgün, N
    Ayaslioglu, E
    Tutkak, H
    Aydintug, OT
    RHEUMATOLOGY INTERNATIONAL, 2005, 25 (01) : 1 - 5